priors.science/reviews/parkinsons-disease-management

Parkinsons Disease Management

The current evidence on 6 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

6claims tracked
57primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
2 Established · 4 Likely · 0 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Levodopa most effective for Parkinson's motor symptomsPD MOTOREstablished87%9
Deep brain stimulation improves motor function in advanced Parkinson'sPD DEVICEEstablished86%10
Monoamine oxidase B inhibitors provide motor benefit in Parkinson'sPD MOTORLikely83%9
No proven disease-modifying therapy in Parkinson'sPD NEUROLikely83%10
Continuous infusion therapy reduces motor fluctuations in advanced Parkinson'sPD DEVICELong-standingLikely82%8
Pimavanserin improves Parkinson's psychosis without worsening motor symptomsPD NMLong-standingLikely81%11
Track Parkinsons Disease Management.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.